GLYMPA

Glympa 25/5mg Tablets 30's

Name: Glympa 25/5mg Tablets 30's
Brand: GLYMPA
SKU: 10119
Price: 3330.00 KES
Availability: InStock

0.0 · 0 Ratings · 0 Reviews ·

KES 3,330

In Stock

Free 4-hour delivery · 8 AM – 8 PM

Overview

This is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitorÂ and linagliptin, aÂ dipeptidyl peptidase-4Â (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GlympaTMÂ is indicated as an adjunct to diet and exercise toÂ improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

GlympaTM 25/5 Tablet: Each film coated tablet contains Empagliflozin INN 25 mg & Linagliptin INN 5 mg.

Directions for Use

he recommended dose of this is 10 mg empagliflozin and 5 mg linagliptin once daily, taken in the morning, with or without food. Dose may be increased to 25 mg empagliflozin and 5 mg linagliptin once daily.

Pancreatitis: There have been reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue this tablet. Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue this tablet, evaluate and treat promptly. Before initiating this tablet, consider risk factors for ketoacidosis. Patients on this tablet may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis.